Bilal Arif
Chief Tech/Sci/R&D Officer bei SAREPTA THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von Bilal Arif
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SAREPTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31.12.2022 | - |
| Corporate Officer/Principal | - | 31.12.2022 |
Karriereverlauf von Bilal Arif
Ehemalige bekannte Positionen von Bilal Arif
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2017 | 02.01.2019 |
Ausbildung von Bilal Arif
| McGill University | Undergraduate Degree |
| Tufts University | Graduate Degree |
| Instituto de Empresa SL | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 4 |
| Kanada | 2 |
| Spanien | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Graduate Degree | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Bilal Arif
- Erfahrung
